Every time we pass the AI Express, an investor asks a question on the investor interactive platform: Hello Secretary of the Board! With the accelerated spread of a new round of mutated coronaviruses around the world, some countries such as the United States are accelerating the research on oral drugs for the new crown. Does your company directly or indirectly provide raw materials for new crown-related drugs to the market of the United States or other countries?If no pleaseannouncementClarification, if so, what stage is the company currently in, such as negotiation stage or a small amount of supply, in the case of not violating trade secret regulations, please truthfully inform the majority of investors, thank you.
Feikai material(300398.SZ) said on the investor interaction platform on January 13 that the company’s pharmaceutical intermediate product customers are mainly domestic API manufacturers, and API manufacturers strictly control the research and development, production process and sales of new drugs. Therefore, The company has no way of knowing which pharmaceutical intermediates it purchases are actually used in the development and production of drugs.
(Article source: Daily Economic News)
Article source: Daily Economic News
Responsible editor: 43
Original title: Feikai Materials: The company has no way of knowing which pharmaceutical intermediates it purchased are actually used in the development and production of drugs
Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.
Scan the QR code to follow
Oriental Fortune official website WeChat